Inspire Medical Systems (NYSE:INSP) Upgraded at UBS Group

Inspire Medical Systems (NYSE:INSP) was upgraded by equities researchers at UBS Group to a “strong sell” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other equities research analysts have also recently weighed in on the company. Mizuho reduced their price objective on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. Robert W. Baird dropped their target price on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. JPMorgan Chase & Co. cut their target price on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating for the company in a research note on Tuesday, May 5th. Oppenheimer reissued a “market perform” rating on shares of Inspire Medical Systems in a report on Monday, June 15th. Finally, Evercore lowered shares of Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 price target on the stock. in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Inspire Medical Systems currently has a consensus rating of “Hold” and a consensus target price of $73.28.

Inspire Medical Systems Stock Up 2.0%

Shares of NYSE:INSP opened at $51.93 on Tuesday. The business has a 50 day moving average price of $45.61 and a 200 day moving average price of $56.43. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The company has a market cap of $1.50 billion, a price-to-earnings ratio of 11.57, a PEG ratio of 5.16 and a beta of 0.71.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The company’s revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Analysts anticipate that Inspire Medical Systems will post 0.93 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of INSP. CWM LLC lifted its position in Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after purchasing an additional 242 shares during the period. EverSource Wealth Advisors LLC increased its holdings in Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after buying an additional 580 shares during the period. Havemeyer Place LP bought a new stake in Inspire Medical Systems in the 4th quarter valued at $39,000. V Square Quantitative Management LLC acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at $40,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after buying an additional 205 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.